Low-Dose of Intrapulmonary Pirfenidone Improves Human Transforming Growth Factorβ1-Driven Lung Fibrosis

• Main Authors: Tomohito Okano, Tetsu Kobayashi, Taro Yasuma, Corina N. D’Alessandro-Gabazza, Masaaki Toda, Hajime Fujimoto, Hiroki Nakahara, Yuko Okano, Atsuro Takeshita, Kota Nishihama, Haruko Saiki, Atsushi Tomaru, Valeria Fridman D’Alessandro, Satoru Ishida, Hiromi Sugimoto, Yoshiyuki Takei, Esteban C. Gabazza
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2020-11-01
• Series: Frontiers in Pharmacology
• Subjects: idiopathic pulmonary fibrosis; pirfenidone; intrapulmonary delivery; oral therapy; adverse effects; drug delivery
• Online Access: https://www.frontiersin.org/articles/10.3389/fphar.2020.593620/full

Idiopathic pulmonary fibrosis is a chronic, progressive, and lethal lung disease of unknown etiology. Antifibrotic drugs, including pirfenidone, are currently used for the treatment of the disease. The oral administration of pirfenidone is an effective therapy, as demonstrated by several clinical trials, although it causes severe adverse events in some patients. We hypothesized that low-dose intrapulmonary delivery of pirfenidone is effective in human transforming growth factorβ1-driven pulmonary fibrosis. To demonstrate our hypothesis, we compared the therapeutic efficacy of varying doses of pirfenidone administered by oral and intranasal routes in a human transforming growth factor-β1 transgenic mouse with established pulmonary fibrosis. We found similar amelioration of lung cell infiltration, inflammatory and fibrotic cytokines, lung fibrosis score, and hydroxyproline content in mice with human transforming growth factor-β1-mediated pulmonary fibrosis treated with low-dose intranasal pirfenidone and high-dose oral pirfenidone. This study showed that pirfenidone is a potent inhibitor of human transforming growth factor-β1-driven lung fibrosis and that intrapulmonary delivery of low-dose pirfenidone produces therapeutic responses equivalent to high-dose of oral pirfenidone.